{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:34:47Z","timestamp":1757619287669,"version":"3.44.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40123-025-01201-3","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T02:35:49Z","timestamp":1753151749000},"page":"2231-2241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous versus Intermittent Use of Tear Substitutes in Patients Treated with Anti-VEGF for Neovascular Age-Related Macular Degeneration: The TREDIA Study"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06174181","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5090-7845","authenticated-orcid":false,"given":"H\u00e9lo\u00efse","family":"Torres-Villaros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Giocanti-Aur\u00e9gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Agard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Billant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Arbousoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Matagrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e8s","family":"Fenniri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Dot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1201_CR1","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Eyes and Vision Group, editor. Cochrane Database of Systematic Reviews"},{"issue":"5","key":"1201_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","volume":"64","author":"J Talks","year":"2019","unstructured":"Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, et al. The use of real-world evidence for evaluating anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2019;64(5):707\u201319.","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"1201_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/ICL.0000000000000828","volume":"47","author":"OA Polat","year":"2021","unstructured":"Polat OA, \u00c7etinkaya Z, Evereklio\u011flu C, Karaca \u00c7, Erkili\u00e7 K. Effect of repeated topical povidone-iodine and antibiotic applications on Meibomian glands and ocular surface parameters in patients with repeated intravitreal injections. Eye Contact Lens. 2021;47(12):651\u20134.","journal-title":"Eye Contact Lens"},{"issue":"4","key":"1201_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/15569527.2017.1291665","volume":"36","author":"H Saedon","year":"2017","unstructured":"Saedon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017;36(4):343\u20136.","journal-title":"Cutan Ocul Toxicol"},{"issue":"2","key":"1201_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/ICL.0000000000001044","volume":"50","author":"E Akbulut","year":"2024","unstructured":"Akbulut E, Kirik F, Ekinci Aslanoglu C, Hekimoglu ER, Haciosmanoglu Aldogan E, Ozdemir MH. The inflammatory and cytological effect of repeated povidone-iodine application in patients receiving intravitreal injections. Eye Contact Lens. 2024;50(2):73\u20138.","journal-title":"Eye Contact Lens"},{"issue":"1","key":"1201_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12886-020-01615-6","volume":"20","author":"S Kim","year":"2020","unstructured":"Kim S, Ahn Y, Lee Y, Kim H. Toxicity of povidone-iodine to the ocular surface of rabbits. BMC Ophthalmol. 2020;20(1):359.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"1201_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0002-9394(14)76094-5","volume":"97","author":"SM Mac Rae","year":"1984","unstructured":"Mac Rae SM, Brown B, Edelhauser HF. The corneal toxicity of presurgical skin antiseptics. Am J Ophthalmol. 1984;97(2):221\u201332.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1201_CR8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/OPX.0000000000001091","volume":"94","author":"WH Ridder","year":"2017","unstructured":"Ridder WH, Oquindo C, Dhamdhere K, Burke J. Effect of povidone iodine 5% on the cornea, vision, and subjective comfort. Optom Vis Sci. 2017;94(7):732\u201341.","journal-title":"Optom Vis Sci"},{"issue":"8","key":"1201_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/aos.14797","volume":"99","author":"S Verrecchia","year":"2021","unstructured":"Verrecchia S, Chiambaretta F, Kodjikian L, Nakouri Y, El Chehab H, Mathis T, et al. A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study. Acta Ophthalmol. 2021;99(8):877\u201384.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"1201_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127\u201340.","journal-title":"Psychol Health Med"},{"issue":"2","key":"1201_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.12968\/ijop.2010.1.2.68","volume":"1","author":"K Henriksen","year":"2010","unstructured":"Henriksen K, Adhami S. Patient experience of intravitreal injections in AMD. Int J Ophthalmic Pract. 2010;1(2):68\u201372.","journal-title":"Int J Ophthalmic Pract"},{"issue":"2","key":"1201_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0264619613481778","volume":"31","author":"C Thetford","year":"2013","unstructured":"Thetford C, Hodge S, Harding S, Taylor S, Knox PC. Living with age-related macular degeneration treatment: patient experiences of being treated with ranibizumab (Lucentis)(R) intravitreal injections. Br J Visual Impairment. 2013;31(2):89\u2013101.","journal-title":"Br J Visual Impairment"},{"issue":"10","key":"1201_CR13","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00417-016-3384-0","volume":"254","author":"H Senra","year":"2016","unstructured":"Senra H, Ali Z, Balaskas K, Aslam T. Psychological impact of anti-VEGF treatments for wet macular degeneration\u2014a review. Graefes Arch Clin Exp Ophthalmol. 2016;254(10):1873\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1201_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1201_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1542-0124(12)70083-6","volume":"5","author":"Methodologies to Diagnose and Monitor Dry Eye Disease","year":"2007","unstructured":"Methodologies to Diagnose and Monitor Dry Eye Disease. Report of the diagnostic methodology subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):108\u201352.","journal-title":"Ocul Surf"},{"issue":"7","key":"1201_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"AJ Bron","year":"2003","unstructured":"Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640\u201350.","journal-title":"Cornea"},{"issue":"4","key":"1201_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181\u201393.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1201_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","volume":"128","author":"KL Miller","year":"2010","unstructured":"Miller KL. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128(1):94.","journal-title":"Arch Ophthalmol"},{"key":"1201_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12174","author":"F Malet","year":"2014","unstructured":"Malet F, Le Goff M, Colin J, Schweitzer C, Delyfer M, Korobelnik J, et al. Dry eye disease in French elderly subjects: the Alienor Study. Acta Ophthalmol. 2014. https:\/\/doi.org\/10.1111\/aos.12174.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"1201_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539\u201374.","journal-title":"Ocul Surf"},{"issue":"2","key":"1201_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102127","volume":"47","author":"M Gao","year":"2024","unstructured":"Gao M, Xia F, Wang P, Feng Z, Wang X. Influence of serial intravitreal injections on measures of dry eye: a systemic review and meta-analysis. Cont Lens Anterior Eye. 2024;47(2): 102127.","journal-title":"Cont Lens Anterior Eye"},{"issue":"3","key":"1201_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/15569520903080511","volume":"28","author":"J Jiang","year":"2009","unstructured":"Jiang J, Wu M, Shen T. The toxic effect of different concentrations of povidone iodine on the rabbit\u2019s cornea. Cutaneous Ocular Toxicol. 2009;28(3):119\u201324.","journal-title":"Cutaneous Ocular Toxicol"},{"issue":"9","key":"1201_CR23","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/bjo.83.9.1019","volume":"83","author":"E Pels","year":"1999","unstructured":"Pels E, Vrensen GFJM. Microbial decontamination of human donor eyes with povidone-iodine: penetration, toxicity, and effectiveness. Br J Ophthalmol. 1999;83(9):1019\u201326.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1201_CR24","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1097\/IAE.0000000000002290","volume":"39","author":"MC Peden","year":"2019","unstructured":"Peden MC, Hammer ME, Su\u00f1er IJ. Dilute povidone-iodine prophylaxis maintains safety while improving patient comfort after intravitreal injections. Retina. 2019;39(11):2219\u201324.","journal-title":"Retina"},{"issue":"8","key":"1201_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.oret.2020.11.008","volume":"5","author":"FS Ali","year":"2021","unstructured":"Ali FS, Jenkins TL, Boparai RS, Obeid A, Ryan ME, Wibblesman TD, et al. Aqueous chlorhexidine compared with povidone-iodine as ocular antisepsis before intravitreal injection: a randomized clinical trial. Ophthalmol Retina. 2021;5(8):788\u201396.","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"1201_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jcjo.2024.01.012","volume":"59","author":"KA Stephenson","year":"2024","unstructured":"Stephenson KA, Merkur A, Kirker A, Albiani D, Pakzad-Vaezi K. Rates of endophthalmitis before and after transition from povidone-iodine to aqueous chlorhexidine asepsis for intravitreal injection. Can J Ophthalmol. 2024;59(6):424\u20139.","journal-title":"Can J Ophthalmol"},{"issue":"8","key":"1201_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/OPX.0b013e318181a947","volume":"85","author":"SE Moss","year":"2008","unstructured":"Moss SE, Klein R, Klein BEK. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008;85(8):668\u201374.","journal-title":"Optom Vis Sci"},{"issue":"3","key":"1201_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ajo.2011.02.026","volume":"152","author":"A Galor","year":"2011","unstructured":"Galor A, Feuer W, Lee DJ, Florez H, Carter D, Pouyeh B, et al. Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population. Am J Ophthalmol. 2011;152(3):377\u201384 (e2).","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1201_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocular Surf. 2017;15(3):575\u2013628.","journal-title":"Ocular Surf"},{"key":"1201_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OPTO.S350185","volume":"15","author":"DA Semp","year":"2023","unstructured":"Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS. Artificial tears: a systematic review. OPTO janv. 2023;15:9\u201327.","journal-title":"OPTO janv"},{"issue":"2","key":"1201_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","volume":"5","author":"The Definition and Classification of Dry Eye Disease","year":"2007","unstructured":"The Definition and Classification of Dry Eye Disease. Report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocular Surf. 2007;5(2):75\u201392.","journal-title":"Ocular Surf"},{"issue":"8","key":"1201_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005296","volume":"4","author":"R Hua","year":"2014","unstructured":"Hua R, Yao K, Hu Y, Chen L. Discrepancy between subjectively reported symptoms and objectively measured clinical findings in dry eye: a population based analysis. BMJ Open. 2014;4(8): e005296.","journal-title":"BMJ Open"},{"issue":"3","key":"1201_CR33","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1167\/iovs.14-15814","volume":"56","author":"D Schmidl","year":"2015","unstructured":"Schmidl D, Witkowska KJ, Kaya S, Baar C, Faatz H, Nepp J, et al. The association between subjective and objective parameters for the assessment of dry-eye syndrome. Investig Ophthalmol Visual Sci. 2015;56(3):1467\u201372.","journal-title":"Investig Ophthalmol Visual Sci."},{"issue":"8","key":"1201_CR34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","volume":"23","author":"KK Nichols","year":"2004","unstructured":"Nichols KK, Nichols JJ, Mph M, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23(8):762\u201370.","journal-title":"Cornea"},{"issue":"2","key":"1201_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/aos.12012","volume":"92","author":"BD Sullivan","year":"2014","unstructured":"Sullivan BD, Crews LA, Messmer EM, Foulks GN, Nichols KK, Baenninger P, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmologica mars. 2014;92(2):161\u20136.","journal-title":"Acta Ophthalmologica mars"},{"key":"1201_CR36","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.2147\/OPTH.S391082","volume":"16","author":"F Pastor-Pascual","year":"2022","unstructured":"Pastor-Pascual F, Pastor-Pascual R, G\u00e1lvez-Perez P, Dolz-Marco R, Gallego-Pinazo R. Use of artificial tears in patients undergoing treatment with anti-VEGF intravitreal injections. OPTH. 2022;16:3959\u201372.","journal-title":"OPTH"},{"issue":"3","key":"1201_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41433-021-01476-3","volume":"36","author":"HD Jin","year":"2022","unstructured":"Jin HD, Surbeck JW, Marsh HR, Ding K, Kingsley RM, Riaz KM, et al. The effect of punctal plugs in reducing ocular surface irritation after povidone-iodine preparation of intravitreal injection\u2014a randomized trial. Eye. 2022;36(3):568\u201374.","journal-title":"Eye"},{"issue":"9","key":"1201_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1089\/jop.2022.0048","volume":"38","author":"M Labetoulle","year":"2022","unstructured":"Labetoulle M, the CBL-101 Study Group, Mortemousque B, Allali J, Blanc P, Bonne M, et al. Performance and safety of a sodium hyaluronate tear substitute with polyethylene glycol in dry eye disease: a multicenter, investigator-masked, randomized, noninferiority trial. J Ocular Pharmacol Ther. 2022;38(9):607\u201316.","journal-title":"J Ocular Pharmacol Ther."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01201-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:11:07Z","timestamp":1757265067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01201-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H\u00e9lo\u00efse Torres-Villaros, Emilie Agard, J\u00e9r\u00e9my Billant, Benjamin Matagrin, Nathalie Arbousoff, and In\u00e8s Fenniri declare that they have no competing interests; Serge Doan reports receiving personal fees from Bausch&Lomb, Horus Pharma, Quantel Medical, Santen, and Th\u00e9a; Audrey Giocanti-Aur\u00e9gan reports receiving personal fees from Abbvie, Apellis, Bayer, Horus Pharma, Roche, Novartis, and Th\u00e9a; Corinne Dot reports receiving personal fees from Abbvie, Bayer, Horus Pharma, Novartis, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients received information on the study and signed a consent form to participate in the study. This study was conducted in accordance with the tenets of the Declaration of Helsinki. It obtained a favorable opinion from our institutional review board (ID-RCB no. 2023-A00620-45; Comit\u00e9 de Protection des Personnes Ouest II, France) according to the principles of Jarde law no. 2012\u2013300, including the decrees of 23 December 2023, on Research Involving the Human Person (called RIPH in French). Data were collected and processed in accordance with the MR-003 reference methodology. The IRB approval covered both study sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The manuscript was linguistically reviewed by Mrs. Sophie Pegorier, a native English-speaking professional specializing in medical translation (Pegorier Traductions, Paris, France). This assistance was funded by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing\/Editorial Assistance"}}]}}